Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cloudbreak Pharma
Its shares trade on HKEX under the ticker 2592.HK. It has been listed since 3 July 2025. In the fiscal year to 31 December 2024, it reported revenue of $10.0m and a net loss of $99.1m. At that date it held total assets of $40.0m and shareholders' equity of −$351.5m.
Cloudbreak Pharma, Inc. is an investment holding company, which engages in the research and development of therapeutic biologics. The company is headquartered in Irvine, California. The company went IPO on 2025-07-03. The firm is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The firm has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Jul 2025
- Employees
- 51
- Website
- cloudbreakpharma.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is focused on in-house discovery, development, and commercialization of ophthalmic therapies.
- Core Products CBT-001 and CBT-009 are in advanced clinical stages with Phase III and completed Phase I/II trials.
- The company employs 51 full-time employees and is headquartered in Irvine, California.
Weaknesses
- The company has only two core products with limited clinical-stage drug candidates.
- Other drug candidates are in early development stages including two clinical-stage and four pre-clinical-stage candidates.
- The company went public via IPO on 2025-07-03, which may indicate limited market history.
Opportunities
- CBT-001 is in Phase III multi-regional clinical trials in the US and China, offering potential global market expansion.
- CBT-009 has completed Phase I/II trials for juvenile myopia, presenting a commercial opportunity in pediatric ophthalmology.
- The firm's focus on proprietary development of ophthalmic therapies may attract investment in biotechnology.
Threats
- The company's limited product portfolio may face competition from established ophthalmic therapies.
- Early-stage drug candidates may fail to progress through clinical trials, increasing development risks.
- The IPO date of 2025-07-03 suggests the company is new to public markets, potentially facing volatility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.